Thyrocare Reports 25% Revenue Growth and INR 45 Crore Impairment Charge in Q2 FY27
Thyrocare Technologies Limited reported a 25.1% year-on-year revenue increase to INR 270.8 crore in Q2 FY27, driven by a 26.7% growth in its Pathology segment. EBITDA rose 24.9% to INR 89.3 crore, and profit after tax before exceptional items increased 25.7% to INR 60.2 crore. A one-time, non-cash impairment charge of INR 45 crore related to the proposed sale of its Nuclear Imaging business reduced net profit to INR 15.2 crore. The company processed 61.6 million tests, maintaining quality with reduced complaints and a 3.49-hour turnaround time.
First-hand measurement across 5 sources
We measured how 5 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (65/100). Lens Score 37/100.
Outlets measured: businessstandard, inc42media, news18, thetribune, freepressjournal. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (50–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
freepressjournal broke this story on 29 Oct, 11:47 am. Other outlets followed.